Taletrectinib for ROS1+ lung cancer with brain spread
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced lung cancer (stage 4) that has spread to other parts of your body.
- Your cancer has a specific change called ROS1 gene fusion, confirmed by a standard lab test.
- You have at least one brain tumor that can be measured on a scan, and any brain symptoms have been stable for the past 2 weeks.
- Your doctor believes the study drug (taletrectinib) could help you, OR you have already taken taletrectinib for 6 months or less.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This study follows people with advanced ROS1-positive non-small cell lung cancer who are taking targeted therapy. It aims to understand how well the treatment works in real life and is for those who haven't had any prior treatment for their lung cancer.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This trial tests a higher dose of the targeted pill firmonertinib combined with two other drugs (bevacizumab and pemetrexed) given into the spine for people with EGFR-mutant lung cancer that has spread to the lining of the brain. It aims to see if this combination can shrink or control the cancer in the central nervous system.
This study tests a new drug called sacituzumab tirumotecan (Sac-TMT) combined with radiation to the brain for people with EGFR-mutant lung cancer that has spread to the brain and has grown despite first-line EGFR inhibitor therapy. The goal is to see if this combination can control the brain tumors better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.